Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 19;3(5):e0438.
doi: 10.1097/CCE.0000000000000438. eCollection 2021 May.

Outcome Improvement Between the First Two Waves of the Coronavirus Disease 2019 Pandemic in a Single Tertiary-Care Hospital in Belgium

Bernard Lambermont  1 , Anne-Françoise Rousseau  1 , Laurence Seidel  2 , Marie Thys  3 , Jonathan Cavalleri  4 , Pierre Delanaye  5 , J Geoffrey Chase  6 , Pierre Gillet  7 , Benoit Misset  1
Affiliations

Outcome Improvement Between the First Two Waves of the Coronavirus Disease 2019 Pandemic in a Single Tertiary-Care Hospital in Belgium

Bernard Lambermont et al. Crit Care Explor. .

Abstract

Objectives: To compare patient management and outcome during the first and second waves of the coronavirus 2019 pandemic.

Design: Single-center prospective cohort study.

Setting: Tertiary-care University Hospital.

Patients: All adult patients admitted in either the first (from March 15 to May 15, 2020) or second (from October 1 to November 30, 2020) wave of coronavirus disease 2019.

Interventions: None.

Measurements and main results: Primary outcome was 30-day mortality. During the second wave of the coronavirus disease 2019 pandemic, 33 patients (4.8%) were transferred due to overcrowding and excluded from analysis. There were 341 (first wave of the coronavirus disease 2019 pandemic) and 695 (second wave of the coronavirus disease 2019 pandemic) coronavirus disease 2019 patients admitted to the hospital, with median age first wave of the coronavirus disease 2019 pandemic as 68 (57-80) and second wave of the coronavirus disease 2019 pandemic as 71 (60-80) (p = 0.15), and similar admission severity. For the first wave of the coronavirus disease 2019 pandemic versus second wave of the coronavirus disease 2019 pandemic, 30-day mortality was 74/341 (22%) and 98/662 (15%) (p = 0.007). In the ward, 11/341 (3.2%) and 404/662 (61%) received dexamethasone (p < 0.001); 6/341 (2%) and 79/662 (12%) received high-flow nasal oxygen (p < 0.0001); 2/341 (0.6%) and 88/662 (13.3%) received remdesivir (p < 0.0001); 249/341 (73%) and 0/662 (0%) received hydroxychloroquine (p < 0.0001); and 87/341 (26%) and 128/662 (19%) (p = 0.024) patients were transferred to ICU. On ICU admission, median Sequential Organ Failure Assessment was 6 (3-7) and 4 (3-6) (p = 0.02). High-flow nasal oxygen was given to 16/87 (18%) and 102/128 (80%) (p < 0.001); 69/87 (79%) and 56/128 (44%) received mechanical ventilation (p < 0.001) with durations 17 days (10-26 d) and 10 days (5-17 d) (p = 0.01). Median ICU length of stay was 14 days (5-27 d) and 6 days (3-11 d) (p < 0.001). Finally, 16/87 (18%) and 8/128 (6%) received renal replacement therapy (p = 0.0055); and 64/87 (74%) and 51/128 (40%) needed vasopressor support (p < 0.001).

Conclusions: The main therapeutic changes between the first wave of the coronavirus disease 2019 pandemic and the second wave of the coronavirus disease 2019 pandemic were use of steroids, unrestrictive use of high-flow nasal oxygen for hypoxemic patients, and transfer of patients to other geographic areas in the case of ICU overcrowding. These changes were associated with a decrease in 30-day mortality, ICU admission, and organ support.

Keywords: coronavirus disease 2019; corticosteroids; high-flow nasal oxygen; intensive care; mechanical ventilation; remdesivir.

PubMed Disclaimer

Conflict of interest statement

The authors have disclosed that they do not have any potential conflicts of interest.

Figures

Figure 1.
Figure 1.
Clinical management of coronavirus disease 2019 patients during the first and second waves of the pandemic. HFNO = high-flow nasal oxygen, RR = respiratory rate.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jamil S, Mark N, Carlos G, et al. : Diagnosis and management of COVID-19 disease. Am J Respir Crit Care Med. 2020; 201:P19–P20 - PubMed
    1. Sanders JM, Monogue ML, Jodlowski TZ, et al. : Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA. 2020; 323:1824–1836 - PubMed
    1. Arabi YM, Fowler R, Hayden FG: Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med. 2020; 46:315–328 - PMC - PubMed
    1. RECOVERY Collaborative Group: Dexamethasone in hospitalized patients with Covid-19. N Eng J Med. 2021; 384:693–704 - PMC - PubMed
    1. Sterne JAC, Murthy S, Diaz JV, et al. ; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA. 2020; 324:1330–1341 - PMC - PubMed